This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System.
Current oncology (Toronto, Ont.) · 2025
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.
HemaSphere · 2024
Immune Checkpoint Inhibitor Exposure in Pregnancy: A Scoping Review.
Journal of immunotherapy (Hagerstown, Md. : 1997) · 2022
Latest funding
- $140,000
Immuno-metabolomic biomarkers predictive of response to chimeric antigen T cell receptor therapy for B cell lymphoma
CIHR · 2024 · Supervisor
- $516,376
Modulating T cell metabolism to enhance the efficacy of adoptive cell therapy
CIHR · 2022 · Nominated PI
- $283,051
Mucosal Associated Invariant T-cells (MAIT cells) as Key Mediators of Anti-Tumor Immune Responses and the Microbiome Effect in Non-Small Cell Lung Cancer (NSCLC)
CIHR · 2019 · Co-investigator
4 publications.
Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System.
Beaudry FEG, Li Z, Borgida A, Zorigtbaatar A, Wang X, Hildebrand M, Hamza O, Jang GH, Bucur R, Dodd A, Wilson J, Auer RC, Saibil S, Tsang ES, Vogel A, O'Kane GM, Gallinger S, Knox JJ, Notta F, Sapisochin G, Grant RC
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.
Gong IY, Tran D, Saibil S, Laister RC, Kuruvilla J
Immune Checkpoint Inhibitor Exposure in Pregnancy: A Scoping Review.
Salehi I, Porto L, Elser C, Singh J, Saibil S, Maxwell C
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events.
Araujo DV, Muniz TP, Yang A, Keshavarzi S, Sorotsky H, Butler MO, Saibil S, Spreafico A, Hogg D
Immuno-metabolomic biomarkers predictive of response to chimeric antigen T cell receptor therapy for B cell lymphoma
Principal investigators: Gong, Inna Y
Keywords: Chimeric Antigen T Cell Receptor Therapy; Immuno-Metabolism; Immunotherapy; Lymphoproliferative Disorders; Metabolomics; Proteomics; T Cell
Modulating T cell metabolism to enhance the efficacy of adoptive cell therapy
Principal investigators: Saibil, Samuel D
Keywords: Adoptive Cell Therapy; Metabolism; Mitochondria; T Cell
Mucosal Associated Invariant T-cells (MAIT cells) as Key Mediators of Anti-Tumor Immune Responses and the Microbiome Effect in Non-Small Cell Lung Cancer (NSCLC)
Principal investigators: Sacher, Adrian G
Keywords: Immunotherapy; Microbiome; Non-Small Cell Lung Cancer; Tumor Immunology
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medical Biophysics
- Biostatistics Division
- Other
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Gonzalo Sapisochin
Faculty
1 shared papers, latest 2025
Arndt Vogel
Faculty
1 shared papers, latest 2025
Steven Gallinger
Medical Biophysics
1 shared papers, latest 2025
Sareh Keshavarzi
Biostatistics Division
1 shared papers, latest 2021
Faiyaz Notta
Medical Biophysics
1 shared papers, latest 2025
Anna Spreafico
Faculty
1 shared papers, latest 2021
John Kuruvilla
Faculty
1 shared papers, latest 2024
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.